Engdahl E, et al. Serological response against HHV-6A is associated with increased risk for multiple sclerosis. Abstract 222. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose